Table 1. Characteristics of the screening population, in total, by screening method, and by baseline results.
| All population | Cytology arm | HPV arm | Cytology Negative | Cytology positive | HPV negative | HPV positive | |
|---|---|---|---|---|---|---|---|
| N | 14,713 | 7,400 | 7,313 | 7,256 | 144 | 6,909 | 404 |
| Mean age in years (SD) | 58.1 (1.31) | 58.1 (1.3) | 58.1 (1.3) | 58.1 (1.3) | 58.0 (1.3) | 58.1 (1.3) | 58.1 (1.4) |
| Median CIN2+ follow up (Q1–Q3) (years) | 5.2 (4.7–8.5) | 6.1 (3.7–8.7) | 5.0 (4.8–7.9) | 6.1 (3.7–8.7) | 5.9 (1.5–8.4) | 5.0 (4.8–7.8) | 6.0 (3.1–8.4) |
| Median cancer follow up (Q1–Q3) (years) | 9.8 (8.9–10.3) | 9.8 (8.9–10.3) | 9.8 (8.9–10.3) | 9.8 (8.9–10.3) | 9.3 (8.8–10.3) | 9.8 (8.9–10.3) | 9.8 (9.0–10.3) |
| Sample year | |||||||
| 2012 | 5,683 (38.6%) | 2,817 (38.1%) | 2,866 (39.2%) | 2,761 (38.0%) | 56 (38.9%) | 2,710 (39.2%) | 156 (38.6%) |
| 2013 | 5,733 (30.9%) | 2,908 (39.3%) | 2,825 (38.6%) | 2,857 (39.4%) | 51 (35.4%) | 2,652 (38.4%) | 173 (42.8%) |
| 2014 | 3,297 (22.4%) | 1,675 (22.6%) | 1,622 (22.2%) | 1,638 (22.6%) | 37 (25.7%) | 1,547 (22.4%) | 75 (18.6%) |
| Median number of tests (range) | 2 (1–18) | 2 (1–18) | 2 (1–17) | 2 (1–12) | 4 (1–18) | 2 (1–11) | 5 (1–17) |
| Cytology test | 1 (0–18) | 1 (1–18) | 0 (0–17) | 1 (1–11) | 3 (1–18) | 0 (0–9) | 4 (1–17) |
| HPV test | 2 (0–14) | 1 (0–11) | 2 (1–14) | 1 (0–10) | 2 (0–11) | 2 (1–8) | 4 (1–14) |
| Screening test | 2 (1–7) | 2 (1–7) | 2 (1–5) | 2 (1–5) | 2 (1–7) | 2 (1–5) | 2 (1–5) |
| Non-screening test | 0 (0–16) | 0 (0–16) | 0 (0–16) | 0 (0–9) | 1 (0–16) | 0 (0–10) | 3 (0–16) |
| Baseline result | |||||||
| Positive | 548 (3.7%) | 144 (1.9%) | 404 (5.5%) | - | 144 (100%) | - | 404 (100%) |
| Screening history | |||||||
| Previous abnormality | 1,208 (8.2%) | 584 (7.9%) | 624 (8.5%) | 566 (7.8%) | 18 (12.5%) | 570 (8.3%) | 54 (13.4%) |
| Previous CIN1+ | 925 (6.3%) | 444 (6.0%) | 481 (6.6%) | 428 (5.9%) | 16 (11.1%) | 439 (6.3%) | 42 (10.4%) |
| Previous CIN2+ | 404 (2.7%) | 187 (2.5%) | 217 (3.0%) | 180 (2.5%) | 7 (4.86%) | 197 (2.9%) | 20 (5.0%) |
| Without any screening history | 254 (1.7%) | 137 (1.9%) | 117 (1.6%) | 130 (1.8%) | 7 (4.9%) | 104 (1.5%) | 13 (3.2%) |
| ICC cumulative incidence proportion over 7 years (95% CI) | 0.08% (0.04%, 0.14%) | 0.10% (0.05%, 0.20%) | 0.06% (0.02%, 0.15%) | 0.10% (0.05%, 0.20%) | - | 0.01% (0.002%, 0.10%) | 0.76% (0.24%, 2.32%) |
Data are present N (%), otherwise indicated.
All population: women participating at baseline; SD, standard deviation; Q1, first quartile; Q3, third quartile; CI, confidence interval; CIN1+, cervical intraepithelial neoplasia grade 1 or worse; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; all lesions were diagnosed by histopathological test; previous abnormality, any previous positive test results before the trial, including HPV, cytology or histopathological test; non-screening test includes non-organized/opportunistic test or symptom-related indicated tests; ICC, invasive cervical cancer; HPV, human papillomavirus.